Next Article in Journal
Characterization of Published Errors in High-Impact Oncology Journals
Previous Article in Journal
Weekly Paclitaxel in Ovarian Cancer—The Latest Success Story
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy

Division of Medical Oncology, McGill University Health Centre, 1650 Cedar, Suite A7-130, Montreal, QC H3G 1A4, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(1), 18-25; https://doi.org/10.3747/co.v18i1.708
Submission received: 3 January 2011 / Revised: 13 January 2011 / Accepted: 21 January 2011 / Published: 1 February 2011

Abstract

Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and PubChem databases by combining the search terms “oxaliplatin” or “platinum” or both, with “clinical trials,” “pharmacokinetics,” and “pharmacodynamics”. Data Extraction and Synthesis: Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect. Conclusions: Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
Keywords: Oxaliplatin; targeted therapy; chemotherapy; mechanism of action Oxaliplatin; targeted therapy; chemotherapy; mechanism of action

Share and Cite

MDPI and ACS Style

Alcindor, T.; Beauger, N. Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy. Curr. Oncol. 2011, 18, 18-25. https://doi.org/10.3747/co.v18i1.708

AMA Style

Alcindor T, Beauger N. Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy. Current Oncology. 2011; 18(1):18-25. https://doi.org/10.3747/co.v18i1.708

Chicago/Turabian Style

Alcindor, Thierry, and N. Beauger. 2011. "Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy" Current Oncology 18, no. 1: 18-25. https://doi.org/10.3747/co.v18i1.708

Article Metrics

Back to TopTop